ERH

Summary

ERH (ERH mRNA splicing and mitosis factor, HGNC:3447) is a protein-coding gene on chromosome 14q24.1, encoding Enhancer of rudimentary homolog (P84090). May have a role in the cell cycle. It is a common-essential gene (DepMap: required in 99.9% of cancer cell lines).

Enables methyl-CpG binding activity. Predicted to be involved in pyrimidine nucleoside metabolic process. Located in midbody and nucleus. Part of methylosome.

Source: NCBI Gene 2079 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 7 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_004450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3447
Approved symbol	ERH
Name	ERH mRNA splicing and mitosis factor
Location	14q24.1
Locus type	gene with protein product
Status	Approved
Aliases	DROER
Ensembl gene	ENSG00000100632
Ensembl biotype	protein_coding
OMIM	601191
Entrez	2079

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000216520, ENST00000555373, ENST00000557016, ENST00000557697, ENST00000862407, ENST00000862408, ENST00000912104, ENST00000912105, ENST00000912106

RefSeq mRNA: 1 — MANE Select: NM_004450 NM_004450

CCDS: CCDS9794

Canonical transcript exons

ENST00000557016 — 4 exons

Exon	Start	End
ENSE00001364872	69394825	69394912
ENSE00001368482	69398231	69398299
ENSE00002495907	69380128	69380640
ENSE00003476020	69386963	69387083

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 282.1127 / max 4180.4168, expressed in 1827 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143886	267.7314	1827
143885	14.3813	1777

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
seminal vesicle	UBERON:0000998	99.16	gold quality
embryo	UBERON:0000922	99.12	gold quality
ganglionic eminence	UBERON:0004023	99.10	gold quality
endometrium epithelium	UBERON:0004811	99.08	gold quality
ventricular zone	UBERON:0003053	99.06	gold quality
choroid plexus epithelium	UBERON:0003911	98.97	gold quality
mammary duct	UBERON:0001765	98.96	gold quality
nasal cavity epithelium	UBERON:0005384	98.89	gold quality
nasal cavity mucosa	UBERON:0001826	98.88	gold quality
adult organism	UBERON:0007023	98.86	gold quality
renal medulla	UBERON:0000362	98.85	gold quality
endometrium	UBERON:0001295	98.82	gold quality
caput epididymis	UBERON:0004358	98.81	gold quality
islet of Langerhans	UBERON:0000006	98.79	gold quality
pigmented layer of retina	UBERON:0001782	98.79	gold quality
pylorus	UBERON:0001166	98.77	gold quality
corpus epididymis	UBERON:0004359	98.77	gold quality
inferior olivary complex	UBERON:0002127	98.72	gold quality
superficial temporal artery	UBERON:0001614	98.70	gold quality
pericardium	UBERON:0002407	98.70	gold quality
cauda epididymis	UBERON:0004360	98.70	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.70	gold quality
type B pancreatic cell	CL:0000169	98.69	gold quality
bronchial epithelial cell	CL:0002328	98.67	gold quality
upper arm skin	UBERON:0004263	98.65	gold quality
pharyngeal mucosa	UBERON:0000355	98.63	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	98.61	gold quality
epithelium of bronchus	UBERON:0002031	98.60	gold quality
bronchus	UBERON:0002185	98.60	gold quality
ileal mucosa	UBERON:0000331	98.58	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	47.99
E-HCAD-10	yes	40.67
E-CURD-112	yes	40.00
E-CURD-122	yes	18.11
E-MTAB-6819	no	379.05
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting ERH, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-2681-5P	99.75	67.64	1655

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 15)

• molecular structure, dimerization and protein-protein interactions (PMID:15794639)
• ERH may be an important transcription regulator that also functions in the control of cell-cycle progression. (PMID:17444515)
• interaction with ERH could block the binding of p21(Cip1/Waf1) by Ciz1 in the cell. When ERH and Ciz1 are coexpressed in HeLa cells, Ciz1 recruits ERH to DNA replication foci (PMID:18081865)
• Enhancer of rudimentary homolog (ERH) overexpression may be implicated in the initiation and/or progression of certain human malignancies. (PMID:18500978)
• ERH contributes to chromosome alignment at the metaphase plate by localizing CENP-E at kinetochore regions. (PMID:22704934)
• Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. (PMID:23236152)
• Identification of amino acid residues of ERH required for its recruitment to nuclear speckles and replication foci (PMID:24015320)
• REVIEW: recent findings indicate that ERH plays an important role in cell cycle through its mRNA splicing activity and is critically required for genomic stability and cancer cell survival (PMID:24078386)
• ERH regulation of RNA processing is needed to ensure faithful DNA replication and repair. (PMID:26100022)
• Data suggest that ERH interacts directly in nucleus with C-terminal Arg-Gly-rich region of SAFB1/SAFB2 and this multimer co-localizes in insoluble nuclear fraction; binding of ERH reverses inhibition exerted by SAFB1/SAFB2 on SRPK1. (ERH = enhancer of rudimentary homolog protein; SAFB = scaffold attachment factor B; SRPK1 = splicing kinase SR protein kinase-1) (PMID:28627136)
• Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition. (PMID:32036222)
• ERH facilitates microRNA maturation through the interaction with the N-terminus of DGCR8. (PMID:33035348)
• Molecular basis for the recognition of CIZ1 by ERH. (PMID:36047590)
• ERH: a plug-and-play protein important for gene silencing and cell cycle progression. (PMID:36334004)
• Upregulated enhancer of rudimentary homolog promotes epithelial-mesenchymal transition and cancer cell migration in lung adenocarcinoma. (PMID:37997813)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	erh	ENSDARG00000032866
mus_musculus	Erh	ENSMUSG00000021131
mus_musculus	Erhrt-ps	ENSMUSG00000063412
rattus_norvegicus	Erhl1	ENSRNOG00000011239
drosophila_melanogaster	e(r)	FBGN0011586
caenorhabditis_elegans		WBGENE00009444
caenorhabditis_elegans		WBGENE00011892

Protein

Protein identifiers

Enhancer of rudimentary homolog — P84090 (reviewed: P84090)

All UniProt accessions (2): P84090, G3V279

UniProt curated annotations — full annotation on UniProt →

Function. May have a role in the cell cycle.

Subunit / interactions. Homodimer. Interacts with POLDIP3. Component of the methylosome, a 20S complex containing at least CLNS1A/pICln, PRMT5/SKB1, WDR77/MEP50, PRMT1 and ERH. Interacts with CHTOP.

Subcellular location. Nucleus.

Tissue specificity. Expressed in all tissues examined.

Similarity. Belongs to the E(R) family.

RefSeq proteins (1): NP_004441* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000781	ERH	Family
IPR035912	EHR_sf	Homologous_superfamily

Pfam: PF01133

UniProt features (16 total): strand 6, helix 4, modified residue 2, initiator methionine 1, chain 1, turn 1, cross-link 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
2NML	X-RAY DIFFRACTION	1.55
7CNC	X-RAY DIFFRACTION	1.6
9RMV	X-RAY DIFFRACTION	1.7
1W9G	X-RAY DIFFRACTION	2
7X39	X-RAY DIFFRACTION	2.85

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P84090-F1	96.07	0.94

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 2, 11, 12

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 212 (showing top): MYOGENIN_Q6, PAL_PRMT5_TARGETS_UP, MORF_UBE2I, KOINUMA_COLON_CANCER_MSI_UP, MORF_HDAC1, HSIAO_HOUSEKEEPING_GENES, CAGCTG_AP4_Q5, GGCNKCCATNK_UNKNOWN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, PUJANA_CHEK2_PCC_NETWORK, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_NUCLEAR_TRANSPORT, GCM_PPP1CC, SOX9_B1, chr14q24

GO Biological Process (2): nucleobase-containing compound metabolic process (GO:0006139), pyrimidine nucleoside metabolic process (GO:0006213)

GO Molecular Function (3): RNA binding (GO:0003723), methyl-CpG binding (GO:0008327), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), midbody (GO:0030496), methylosome (GO:0034709)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
primary metabolic process	1
nucleoside metabolic process	1
pyrimidine-containing compound metabolic process	1
nucleic acid binding	1
nucleotide binding	1
sequence-specific DNA binding	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
cytoplasm	1
methyltransferase complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

220 interactions, top by confidence:

A	B	Type	Score
CHTOP	ERH	psi-mi:“MI:0915”(physical association)	0.850
ERH	CHTOP	psi-mi:“MI:0915”(physical association)	0.850
ERH	TASOR2	psi-mi:“MI:0915”(physical association)	0.800
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
THOC1	EIF4A3	psi-mi:“MI:0914”(association)	0.660
NCBP1	KPNA3	psi-mi:“MI:0914”(association)	0.640
SF3B1	SAP18	psi-mi:“MI:0914”(association)	0.640
THOC1	DDX39A	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
ERH	SNRPD3	psi-mi:“MI:0914”(association)	0.580
ERH	SNRPD3	psi-mi:“MI:0915”(physical association)	0.580
ERH	TASOR2	psi-mi:“MI:0915”(physical association)	0.560
TASOR2	ERH	psi-mi:“MI:0915”(physical association)	0.560
PSMA6	ERH	psi-mi:“MI:0915”(physical association)	0.560
ERH	CHTOP	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	ERH	psi-mi:“MI:0915”(physical association)	0.560
ERH	CENPH	psi-mi:“MI:0915”(physical association)	0.560
	ERH	psi-mi:“MI:0915”(physical association)	0.560
ATP6V0C	ERH	psi-mi:“MI:0915”(physical association)	0.560
ERH	UPRT	psi-mi:“MI:0915”(physical association)	0.560
MAPT	KIF2A	psi-mi:“MI:0914”(association)	0.530
NCBP3	SAP18	psi-mi:“MI:0914”(association)	0.530
ZNF597	HCFC1	psi-mi:“MI:0914”(association)	0.530

BioGRID (350): CHTOP (Two-hybrid), FAM208B (Two-hybrid), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Synthetic Lethality), FAM208B (Two-hybrid), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS), ERH (Affinity Capture-Western), ERH (Affinity Capture-MS), ERH (Affinity Capture-MS)

ESM2 similar proteins: A1ANL2, A6TEZ3, B3E2A4, O64300, P03780, P04546, P04716, P07716, P13330, P13951, P27569, P39508, P44210, P44668, P58349, P64467, P64468, P64469, P64470, P69622, P69623, P84089, P84090, Q02408, Q02885, Q05301, Q08052, Q0T4F2, Q0THK2, Q1RBH1, Q24337, Q31NB2, Q320Y2, Q32FE8, Q38168, Q39290, Q3SZC0, Q3Z1Y0, Q44178, Q59461

Diamond homologs: P69099, P69100, P80230, P84089, P84090, Q20057, Q22640, Q24337, Q3SZC0, Q86A92, Q93104, Q94554, Q96319, Q98874, G2TRN4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 177 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	5	23.7×	9e-05
mRNA 3’-end processing	15	22.0×	3e-14
Transport of Mature Transcript to Cytoplasm	7	19.9×	3e-06
RNA Polymerase II Transcription Termination	11	18.0×	1e-09
Transport of Mature mRNA derived from an Intron-Containing Transcript	14	15.9×	2e-11
mRNA Splicing	17	13.9×	6e-13
mRNA Splicing - Minor Pathway	8	13.4×	8e-06
Processing of Capped Intron-Containing Pre-mRNA	20	12.3×	3e-14

GO biological processes:

GO term	Partners	Fold	FDR
U2-type prespliceosome assembly	7	26.5×	1e-06
negative regulation of mRNA splicing, via spliceosome	5	23.2×	3e-04
mRNA export from nucleus	12	21.5×	1e-10
spliceosomal snRNP assembly	6	21.1×	6e-05
spliceosomal complex assembly	5	18.2×	9e-04
stress granule assembly	5	18.2×	9e-04
mRNA splicing, via spliceosome	25	13.9×	1e-18
regulation of alternative mRNA splicing, via spliceosome	8	11.8×	6e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

7 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

887 predictions. Top by Δscore:

Variant	Effect	Δscore
14:69380641:C:CC	acceptor_gain	1.0000
14:69386957:A:AC	donor_gain	1.0000
14:69386958:C:CC	donor_gain	1.0000
14:69386960:TA:T	donor_loss	1.0000
14:69386961:A:AC	donor_gain	1.0000
14:69386961:A:AT	donor_loss	1.0000
14:69386961:ACAC:A	donor_gain	1.0000
14:69386962:C:CC	donor_gain	1.0000
14:69386962:CA:C	donor_gain	1.0000
14:69386962:CACC:C	donor_gain	1.0000
14:69386962:CACCA:C	donor_gain	1.0000
14:69387079:AACAC:A	acceptor_gain	1.0000
14:69387081:CAC:C	acceptor_gain	1.0000
14:69394820:CTCA:C	donor_loss	1.0000
14:69394821:TCA:T	donor_loss	1.0000
14:69394822:CACCT:C	donor_loss	1.0000
14:69394823:A:AT	donor_loss	1.0000
14:69394824:C:CT	donor_loss	1.0000
14:69394908:TGAGA:T	acceptor_gain	1.0000
14:69394909:GAGA:G	acceptor_gain	1.0000
14:69394910:AGA:A	acceptor_gain	1.0000
14:69394911:GA:G	acceptor_gain	1.0000
14:69394913:C:CC	acceptor_gain	1.0000
14:69394913:CTGCA:C	acceptor_loss	1.0000
14:69394914:T:C	acceptor_loss	1.0000
14:69380636:GGTAA:G	acceptor_gain	0.9900
14:69380637:GTAA:G	acceptor_gain	0.9900
14:69380638:TAA:T	acceptor_gain	0.9900
14:69380638:TAACT:T	acceptor_loss	0.9900
14:69380639:AA:A	acceptor_gain	0.9900

AlphaMissense

690 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:69380589:T:A	K88N	1.000
14:69380589:T:G	K88N	1.000
14:69380597:A:G	W86R	1.000
14:69380597:A:T	W86R	1.000
14:69386968:G:C	C69W	1.000
14:69386995:G:C	F60L	1.000
14:69386995:G:T	F60L	1.000
14:69386997:A:G	F60L	1.000
14:69387021:A:G	Y52H	1.000
14:69387056:A:G	L40P	1.000
14:69394832:G:C	C28W	1.000
14:69394858:C:G	A20P	1.000
14:69394865:T:A	R17S	1.000
14:69394865:T:G	R17S	1.000
14:69380569:A:G	L95P	0.999
14:69380590:T:A	K88I	0.999
14:69380595:C:A	W86C	0.999
14:69380595:C:G	W86C	0.999
14:69380601:T:A	K84N	0.999
14:69380601:T:G	K84N	0.999
14:69380618:A:G	Y79H	0.999
14:69386966:A:G	L70P	0.999
14:69386969:C:T	C69Y	0.999
14:69386970:A:G	C69R	0.999
14:69386975:A:G	L67P	0.999
14:69386978:T:A	D66V	0.999
14:69386996:A:G	F60S	0.999
14:69387001:A:C	F58L	0.999
14:69387001:A:T	F58L	0.999
14:69387003:A:G	F58L	0.999

dbSNP variants (sampled 300 via entrez): RS1000002856 (14:69381483 T>C), RS1000200655 (14:69397360 C>T), RS1000614845 (14:69397586 C>T), RS1000639166 (14:69391510 T>G), RS1000755381 (14:69386116 C>T), RS1000839690 (14:69395302 A>T), RS1000869108 (14:69395657 A>G), RS1000950375 (14:69389703 T>C), RS1001033053 (14:69383902 C>G), RS1001051813 (14:69390259 A>G), RS1001108228 (14:69384123 C>A,G,T), RS1001210292 (14:69394340 T>C), RS1001371147 (14:69382522 C>A), RS1001382931 (14:69390028 G>A), RS1001442954 (14:69382710 G>A)

Disease associations

OMIM: gene MIM:601191 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST90002389_288	Lymphocyte percentage of white cells	2.000000e-12
GCST90002399_356	Neutrophil percentage of white cells	2.000000e-17

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725195 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.05	Kd	8.954	nM	CHEMBL3752910
8.05	ED50	8.954	nM	CHEMBL3752910
6.84	Kd	143	nM	MOLIBRESIB
6.64	IC50	230	nM	MOLIBRESIB
6.09	Kd	806.5	nM	CHEMBL5653589
6.09	ED50	806.5	nM	CHEMBL5653589

PubChem BioAssay actives

4 with measured affinity, of 11 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148332: Binding affinity to human ERH incubated for 45 mins by Kinobead based pull down assay	kd	0.0090	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179228: Binding affinity against ERH (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.1430	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148332: Binding affinity to human ERH incubated for 45 mins by Kinobead based pull down assay	kd	0.8065	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	3
Air Pollutants	decreases expression, affects expression, increases abundance	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
bisphenol F	affects cotreatment, increases expression	1
bufotalin	increases expression	1
triphenyl phosphate	affects expression	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, affects localization	1
arsenite	affects binding, increases reaction	1
sodium arsenite	increases expression	1
2-bromopalmitate	increases palmitoylation, decreases reaction, increases abundance	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
CD 437	decreases expression	1
chloropicrin	decreases expression	1
K 7174	decreases expression	1
Arsenic Trioxide	decreases expression	1
Arsenic	increases ubiquitination	1
Benztropine	increases expression	1
Cadmium	increases abundance, increases palmitoylation, decreases reaction	1
Cannabidiol	increases expression	1
Clozapine	increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Furaldehyde	affects cotreatment, affects localization, decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	affects expression, affects response to substance	1
Methotrexate	decreases expression	1
Ozone	affects expression, increases abundance	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651374	Binding	Binding affinity to human ERH incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.